Neoadjuvant chemoradiation therapy for resectable esophago-gastric adenocarcinoma: a meta-analysis of randomized clinical trials
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Neoadjuvant chemoradiation therapy for resectable esophago-gastric adenocarcinoma: a meta-analysis of randomized clinical trials ; volume:15 ; number:1 ; day:28 ; month:4 ; year:2015 ; pages:1-9 ; date:12.2015
BMC cancer ; 15, Heft 1 (28.4.2015), 1-9, 12.2015
- Creator
-
Fu, Tao
- Contributor
-
Bu, Zhao-De
Li, Zi-Yu
Zhang, Lian-Hai
Wu, Xiao-Jiang
Wu, Ai-Wen
Shan, Fei
Ji, Xin
Dong, Qiu-Shi
Ji, Jia-Fu
SpringerLink (Online service)
- DOI
-
10.1186/s12885-015-1341-7
- URN
-
urn:nbn:de:1111-2016110619350
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:51 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Fu, Tao
- Bu, Zhao-De
- Li, Zi-Yu
- Zhang, Lian-Hai
- Wu, Xiao-Jiang
- Wu, Ai-Wen
- Shan, Fei
- Ji, Xin
- Dong, Qiu-Shi
- Ji, Jia-Fu
- SpringerLink (Online service)
Other Objects (12)
Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma
Neoadjuvant chemoradiation therapy for borderline pancreatic adenocarcinoma: report of two cases
Long-Term Postsurgical Outcomes of Neoadjuvant Chemoradiation (CROSS) Versus Chemotherapy (FLOT) for Multimodal Treatment of Adenocarcinoma of the Esophagus and the Esophagogastric Junction
Preoperative docetaxel, cisplatin, and 5-fluorouracil for resectable locally advanced esophageal and esophagogastric junctional adenocarcinoma
Prognostic and predictive biomarkers for response to neoadjuvant chemoradiation in esophageal adenocarcinoma
CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma
Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis
Distribution of lymph node metastases in esophageal adenocarcinoma after neoadjuvant chemoradiation therapy: a prospective study
Neoadjuvant relatlimab and nivolumab in resectable melanoma
A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma
Adjuvant and Neoadjuvant Treatments for Resectable Hepatocellular Carcinoma
DUPAN-II normalisation as a biological indicator during preoperative chemoradiation therapy for resectable and borderline resectable pancreatic cancer
Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma
Neoadjuvant chemoradiation therapy for borderline pancreatic adenocarcinoma: report of two cases
Long-Term Postsurgical Outcomes of Neoadjuvant Chemoradiation (CROSS) Versus Chemotherapy (FLOT) for Multimodal Treatment of Adenocarcinoma of the Esophagus and the Esophagogastric Junction
Preoperative docetaxel, cisplatin, and 5-fluorouracil for resectable locally advanced esophageal and esophagogastric junctional adenocarcinoma
Prognostic and predictive biomarkers for response to neoadjuvant chemoradiation in esophageal adenocarcinoma
CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma
Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis
Distribution of lymph node metastases in esophageal adenocarcinoma after neoadjuvant chemoradiation therapy: a prospective study
Neoadjuvant relatlimab and nivolumab in resectable melanoma
A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma
Adjuvant and Neoadjuvant Treatments for Resectable Hepatocellular Carcinoma
DUPAN-II normalisation as a biological indicator during preoperative chemoradiation therapy for resectable and borderline resectable pancreatic cancer
Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma
Neoadjuvant chemoradiation therapy for borderline pancreatic adenocarcinoma: report of two cases
Long-Term Postsurgical Outcomes of Neoadjuvant Chemoradiation (CROSS) Versus Chemotherapy (FLOT) for Multimodal Treatment of Adenocarcinoma of the Esophagus and the Esophagogastric Junction
Preoperative docetaxel, cisplatin, and 5-fluorouracil for resectable locally advanced esophageal and esophagogastric junctional adenocarcinoma
Prognostic and predictive biomarkers for response to neoadjuvant chemoradiation in esophageal adenocarcinoma
CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma
Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis
Distribution of lymph node metastases in esophageal adenocarcinoma after neoadjuvant chemoradiation therapy: a prospective study
Neoadjuvant relatlimab and nivolumab in resectable melanoma
A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma
Adjuvant and Neoadjuvant Treatments for Resectable Hepatocellular Carcinoma